-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanjing Leads Biolabs says China regulator puts LBL-024 EP-NEC filing in priority review

PUBT·07/10/2026 04:28:11
Listen to the news
Nanjing Leads Biolabs says China regulator puts LBL-024 EP-NEC filing in priority review
  • Nanjing Leads Biolabs’ China BLA for LBL-024 (opamtistomig) in advanced EP-NEC entered NMPA-CDE priority review.
  • Priority review targets 130 working days versus 200 under standard review, improving visibility on a potential approval timeline.
  • Filing covers monotherapy use in patients whose disease progressed after two or more prior systemic treatment lines.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12240599), on July 10, 2026, and is solely responsible for the information contained therein.